Results 161 to 170 of about 18,928 (205)
Challenges and prospects of <i>CYP2C19</i> genotype-guided clopidogrel therapy from the perspective of precision medicine. [PDF]
Front PharmacolWang Z, Fu X, Zhang G.
europepmc +1 more source
Secondary prevention of acute coronary syndromes: a summary of the new 2025 Australian guideline. [PDF]
Aust PrescrJust J, Brieger D, Bennett A, Briffa T.
europepmc +1 more source
Impact of Area-Level Socioeconomic Deprivation on Post-PCI Outcomes Stratified by P2Y<sub>12</sub> Inhibitor Therapy. [PDF]
JACC AdvMalavé JG +12 more
europepmc +1 more source
The role of cangrelor in acute and high-risk PCI settings. [PDF]
Eur Heart J Cardiovasc PharmacotherZeymer U +3 more
europepmc +1 more source
Hemorrhage Risk Associated with Anticoagulant and Antiplatelet Drug Combinations: Insights from the USFDA Adverse Event Reporting System. [PDF]
J Clin MedSridharan K, Sivaramakrishnan G.
europepmc +1 more source
Management of STEMI in an Ectatic and Tortuous Right Coronary Artery Using a Flexible Guide Catheter Extension: A Case Report. [PDF]
Case Rep CardiolToyama Y, Okabe S, Hashimoto T.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Hämostaseologie, 2012
SummaryThe antithrombotic therapy in patients with atherosclerotic vascular disease is subject of several new therapeutic approaches. Simultaneous treatment with aspirin and a thienopyridin (clopidogrel) represents the standard of care for patients with acute coronary syndrome and following coronary stenting recommended by many guidelines. Without true
Antonio, Tello-Montoliu +2 more
+10 more sources
SummaryThe antithrombotic therapy in patients with atherosclerotic vascular disease is subject of several new therapeutic approaches. Simultaneous treatment with aspirin and a thienopyridin (clopidogrel) represents the standard of care for patients with acute coronary syndrome and following coronary stenting recommended by many guidelines. Without true
Antonio, Tello-Montoliu +2 more
+10 more sources
International Journal of Cardiology, 2013
Recently, clopidogrel has beenproved to be reduced or complete lack of clinical benefit in nonsmokers in post-hoc analysis of several largescale randomized controlled trials (RCTs). These observations raise concerns about the costs and potential risks incurred by treating nonsmokers with clopidogrel [1].
Yicong, Ye +3 more
openaire +2 more sources
Recently, clopidogrel has beenproved to be reduced or complete lack of clinical benefit in nonsmokers in post-hoc analysis of several largescale randomized controlled trials (RCTs). These observations raise concerns about the costs and potential risks incurred by treating nonsmokers with clopidogrel [1].
Yicong, Ye +3 more
openaire +2 more sources